Welcome to our dedicated page for PARK HA BIOLOGICAL TECHNOLOGY news (Ticker: PHH), a resource for investors and traders seeking the latest updates and insights on PARK HA BIOLOGICAL TECHNOLOGY stock.
Park Ha Biological Technology (PHH) delivers specialized skincare solutions through innovative formulations targeting problematic skin. This news hub provides investors and industry observers with essential updates on the company's strategic developments in cosmetic science and retail expansion.
Track PHH's latest financial announcements, product innovations, and partnership agreements. Our curated collection includes earnings disclosures, research breakthroughs, and franchise network growth updates - all critical for understanding the company's position in China's competitive beauty market.
The company's unique integration of direct-to-consumer sales and franchise alliances creates multiple growth channels worth monitoring. Stay informed about regulatory developments affecting dermatological products and emerging trends in specialized skincare through PHH's official communications.
Bookmark this page for streamlined access to verified corporate announcements. Regular updates ensure you never miss critical information about PHH's operational strategies and market leadership in cosmetic innovation.
Park Ha Biological Technology (Nasdaq: PHH) has successfully completed its Initial Public Offering, raising $4.8 million through the sale of 1,200,000 ordinary shares at $4.00 per share. Trading began on the Nasdaq Capital Market on December 27, 2024, under the symbol 'PHH'.
The company, which specializes in private skincare labels, direct sales, and franchise alliance promotions, has granted underwriters a 45-day option to purchase up to 180,000 additional shares. The net proceeds will be used to expand directly-owned stores in China, purchase product patents for proprietary development, and acquire ingredient suppliers to reduce production costs.
Dawson James Securities and D. Boral Capital served as underwriters for this firm commitment offering.
Park Ha Biological Technology, a Chinese skincare company, announced the pricing of its Initial Public Offering (IPO) of 1,200,000 ordinary shares at $4.00 per share, expecting to raise $4.8 million in gross proceeds. The shares will trade on the Nasdaq Capital Market under symbol PHH starting December 27, 2024.
The underwriters have a 45-day option to purchase up to 180,000 additional shares. The IPO proceeds will fund expansion of directly-owned stores in China, purchase of product patents for proprietary products, and acquisition of ingredient suppliers to reduce production costs. Dawson James Securities and D. Boral Capital are serving as underwriters for the offering, which is expected to close around December 30, 2024.
FAQ
What is the current stock price of PARK HA BIOLOGICAL TECHNOLOGY (PHH)?
What is the market cap of PARK HA BIOLOGICAL TECHNOLOGY (PHH)?
